Anne Covey, MD, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant.
Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant. Covey says this group of patients is around 80% of those diagnosed with HCC, and the most common form of therapy is locoregional treatment, or therapy targeted to the liver.
Covey says some beneficial locoregional therapies offered to patients with HCC are bland embolization, chemoembolization, radioembolization, embolization with drug-eluding beads, and ablation.
Guideline Spotlights Early-Line Agents for GEP-NETs
November 29th 2023New guidelines for gastroenteropancreatic neuroendocrine tumors were issued by the American Society of Clinical Oncology and geared toward community oncologists who often encounter these rare and complex cases infrequently.
Read More
Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens
November 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.
Read More
Holloway Discusses the Rationale for PARP Inhibition in Advanced Ovarian Cancer
November 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Holloway, MD, explored the state of PARP inhibitors for patients with advanced ovarian cancer including the PRIMA trial of niraparib.
Read More